BioNxt Solutions (TSE:BNXT) has released an update.
BioNxt Solutions Inc. has announced a new letter of intent with Gen-Plus GmbH & Co KG, signaling potential collaborative efforts in pharmaceutical product development, clinical trial planning, and manufacturing. This partnership could enhance BioNxt’s impact on the multiple sclerosis market, where its proprietary Cladribine ODF dosage form targets a market expected to reach USD 41 billion by 2033.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.
